The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome

• Published in: Biomedicine & pharmacotherapy 2022-09, Vol.153, p.113445-113445, Article 113445
• Main Authors: Diez-Echave, Patricia, Vezza, Teresa, Algieri, Francesca, Ruiz-Malagón, Antonio Jesús, Hidalgo-García, Laura, García, Federico, Morón, Rocío, Sánchez, Manuel, Toral, Marta, Romero, Miguel, Duarte, Juan, Garrido-Mesa, José, Rodríguez-Cabezas, María Elena, Rodríguez-Nogales, Alba, Gálvez, Julio
• Format: Article
• Language: English
• Subjects: Agomelatine; Melatonin; Metabolism; Metformin; Microbiome; Obesity
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2022.113445

Melatonin has shown beneficial effects on obesity, both in humans and experimental models, via regulating the altered circadian rhythm and thus ameliorating the gut dysbiosis associated with this metabolic condition. However, its clinical use is limited, mostly due to its short half-life. Agomelatine is an agonist of the melatonin receptors that could be used to manage obesity and offer a better profile than melatonin. Male C57BL/6 mice were fed a high fat diet and orally treated for five weeks with agomelatine, or melatonin or metformin, used as control drugs. Metabolic profile, inflammatory status, vascular dysfunction and intestinal microbiota composition were assessed. Agomelatine lessened body weight gain, enhanced glucose and lipid metabolisms, and improved insulin resistance. It also reduced the obesity-associated inflammatory status and endothelial dysfunction, probably linked to its effect on gut dysbiosis, consisting of the restoration of bacterial populations with key functions, such as short chain fatty acid production. Agomelatine can be considered as a novel therapeutic tool for the management of human obesity and its associated comorbidities. [Display omitted]